Pharmacology of an antiandrogen, anandron, used as an adjuvant therapy in the treatment of prostate cancer.

@article{Moguilewsky1986PharmacologyOA,
  title={Pharmacology of an antiandrogen, anandron, used as an adjuvant therapy in the treatment of prostate cancer.},
  author={Martine Moguilewsky and Jean Fiet and Colette Tournemine and Jean Pierre Raynaud},
  journal={Journal of steroid biochemistry},
  year={1986},
  volume={24 1},
  pages={
          139-46
        }
}
To improve the inhibition of prostate cancer growth obtained by surgical or chemical castration (estrogens or LHRH analogs), blockade of the action of residual androgens of adrenal origin has been proposed. Among antiandrogens acting through the androgen receptor (AR), the nonsteroid anandron (RU 23908) has several advantages over available compounds: megestrol acetate and cyproterone acetate, both steroids, bind substantially to other hormone receptors (progestin, gluco- and mineralocorticoid… Expand
Pharmacology of antiandrogens and value of combining androgen suppression with antiandrogen therapy.
TLDR
Nilutamide counteracts the trophic effect of adrenal androgens left intact by castration, which can only be suppressed by treatments that also suppress corticoid synthesis, and has been shown in the rat treated with buserelin. Expand
Effects of steroidal and non-steroidal antiandrogens on the androgen binding properties of the rat ventral prostate androgen receptor.
TLDR
The results show that antiandrogens are not 'pure' antagonists of androgen action and they are potent agonists in the absence of testosterone and testosterone alone or antiandrogen per se regulate AR levels acutely by protein-synthesis dependent mechanisms of action, in rat ventral prostate. Expand
Design of Novel Anti-Endocrine Agents
TLDR
Oestradiol and dihydrotestosterone have much higher binding affinities for their respective receptors than oestrone or testosterone and are the principal steroids controlling proliferation in breast and prostatic cancer, respectively. Expand
Stimulation of erythropoiesis by the non-steroidal anti-androgen nilutamide in men with prostate cancer: evidence for an agonistic effect?
TLDR
While the stimulation of erythropoiesis induced by the anti-androgen might be due to incomplete neutralisation of endogenous androgens at the bone marrow level, a cell-specific agonistic effect of the drug cannot be excluded, thus calling into question the designation of pure antagonists which has been attributed to this class of compounds. Expand
How the study of the biological activities of antiandrogens can be oriented towards the clinic.
TLDR
The biological strategy that has led to the selection of a systemic and a topical antiandrogen has consisted in successively performing in vitro assays which measure an effect at a specific level in the mechanism of anti androgen action, e.g. interaction with the androgen receptor. Expand
Rat prostatic weight regression in reaction to ketoconazole, cyproterone acetate, and RU 23908 as adjuncts to a depot formulation of gonadotropin-releasing hormone analogue.
TLDR
The effects of the s.c. administration of a depot formulation of the luteinizing hormone-releasing hormone (LHRH) analogue Zoladex were studied in normal male rats to investigate whether these antiandrogens might prevent the LHRH-A-induced initial increase in these parameters. Expand
Pharmacological and clinical studies of the antiandrogen Anandron.
TLDR
As shown in 4 different double blind studies performed in stage D2 prostrate cancer patients, the combination of Anandron with surgical or chemical castration enhanced the beneficial effects of castration alone and thus seems a step forward in the hormonal treatment of prostatic carcinoma. Expand
Growth-stimulating effect of adrenal androgens on the R3327 Dunning prostatic carcinoma
TLDR
In spite of androgen ablation, tumor progression could be induced by exogenous adrenal androgens. Expand
Comparison of Total Androgen Blockade and Orchiectomy in Metastatic Cancer of Prostate
TLDR
A double-blind, randomized study comparing these two modes of treatment was initiated to test the claim that total androgen blockade gives much better results than simple testicular androgen ablation in metastatic prostate cancer. Expand
Nilutamide: An Antiandrogen for the Treatment of Prostate Cancer
TLDR
Nilutamide does not appear to represent a major advance in the treatment of advanced prostate cancer and appears to be somewhat inferior to both flutamide and bicalutamide with regard to adverse effects. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 40 REFERENCES
The pure antiandrogen ru 23908 (anandron®), a candidate of choice for the combined antihormonal treatment of prostatic cancer: A review
The nonsteroidal antiandrogen RU 23908 (AnandronR) weakly interacts with the prostatic cytosolic androgen receptor and shows a fast dissociation rate. When administered to immature castrated rats upExpand
Biological studies on an anti-androgen (SH 714).
TLDR
This compound is strongly anti-androgenic in testosterone-stimulated, orchiectomized rats and in intact male rats when administered either subcutaneously or orally, and at high doses, possesses anti-gonadotropin activity. Expand
New hormonal therapy in prostatic carcinoma: combined treatment with an LHRH agonist and an antiandrogen.
TLDR
It is indicated that a combined hormonal therapy which neutralizes all androgenic influences on peripheral tissues is of potential benefit in prostatic cancer and should minimize the development of metastases and androgen-resistant cell clones. Expand
Comparison of various hormonal therapies for prostatic carcinoma.
TLDR
Megestrol acetate, the only antiandrogen currently available for use in the United States, has been shown to block androgen from all sources and produces a transient reduction in plasma testosterone to levels somewhat higher than those in castrated men. Expand
Action of a non-steroid anti-androgen, RU 23908, in peripheral and central tissues.
Abstract RU 23908 (5,5-dimethyl-3-[4-nitro-3-(trifluoromethyl)phenyl]-2,4-imidazolidinedione) is a non-steroid anti-androgen with potent peripheral and central activity. In the rat, it inhibitsExpand
The effect of ACTH on plasma testosterone and androstenedione concentrations in patients with prostatic carcinoma.
TLDR
The work provides further evidence that in the patient being treated with oestrogen for carcinoma of the prostate a rise in plasma testosterone concentration will result from an increased secretion of ACTH. Expand
Steroid levels in cancer of the prostate--markers of tumour differentiation and adequacy of anti-androgen therapy.
TLDR
In previously untreated patients with Stage D carcinoma, DHT tissue concentrations were correlated with objective responses of patients to anti-androgen treatment, and if tissue DHT levels greater than 2.0 ng/g are considered indicative of tumour “differentiation”, a positive correlation between “ differentiated” DHT Levels and response to treatment was noted. Expand
Combined long‐term treatment with an LHRH agonist and a pure antiandrogen blocks androgenic influence in the rat
TLDR
The present data show that blockage of the Δ4‐steroidogenic pathway induced by treatment with an LHRH agonist prevents the escape phenomenon observed during long‐term treatment with a pure antiandrogen, and permits maximal inhibitory effects of the two treatments on secondary sex organ weight. Expand
Androgenic properties and adrenal depressant activity of megestrol acetate observed in castrated male rats.
TLDR
The investigation shows that megesterol acetate has weak androgenic properties which are apparent at a dose per kg body weight approximately 200 times greater than that used in the treatment of prostatic diseases in man. Expand
Estrogen regulation of rat prostate androgen receptor.
TLDR
Results which suggest that the increase in androgen binding sites observed after estrogen treatment could be mediated by the estrogen receptor are discussed in relation to the pharmacological and pathological effects of estrogens on the prostate. Expand
...
1
2
3
4
...